Abstract BACKGROUND: We reported that some, but not all single nucleotide polymorphisms (SNPs) in
(OR = 1.33, 95% CI 1.02-1.74; P-trend = 0.04), rs3747531 (C) in MSR1 (OR = 0.55, 95% CI 0.32-0.95; P-trend = 0.03), and possibly rs4073 (A) in IL8 (OR = 0.81, 95% CI 0.64-1.01, P-trend = 0.06) were associated with higher-(Gleason 7-10; N = 222), but not lower-(Gleason 2-6; N = 380) grade prostate cancer. In men with low PSA (<2 ng/mL), these higher-grade disease associations were attenuated and/or no longer significant, whereas associations with higher-grade disease were apparent for minor alleles of rs1800795 (C: OR = 0.70, 95% CI 0.51-0.94, P-trend = 0.02) and rs1800797 (A: OR = 0.72, 95% CI 0.53-0.98, P-trend = 0.04) in IL6.
While some IL10 tagSNPs were associated with lower-and higher-grade prostate cancer, distributions of IL10 haplotypes did not differ, except possibly between higher-grade cases and controls among those with low PSA (P = 0.07). We did not observe an association between the studied SNPs and intraprostatic inflammation in the controls.
CONCLUSION: In the PCPT finasteride arm, variation in genes involved in the immune response, including possibly IL8 and IL10 as in the placebo arm, may be associated with prostate cancer, especially higher-grade disease, but not with intraprostatic inflammation. We cannot rule out PSA-associated detection bias or chance due to multiple testing.
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| INTRODUCTION
Finasteride, a drug that inhibits the enzyme (5α-reductase type 2) which catalyzes the conversion of testosterone to dihydrotestosterone in the prostate, 1 decreased the 7-year period prevalence of prostate cancer compared with placebo in the Prostate Cancer Prevention Trial (PCPT). 2 We previously hypothesized that finasteride might reduce risk of this cancer by influencing intraprostatic inflammation. In the placebo arm of PCPT we observed an association between inflammation and prostate cancer, especially higher-grade disease 3 ; in the finasteride arm we did not observe an association. 4 We did, however, find that prevalence and extent of inflammation were higher in the finasteride than placebo arm. 4 We also reported in the placebo arm that some variants in select genes involved in the immune response, including in IL8 and IL10,
were associated with risk of prostate cancer, including higher-grade disease. 5 These variants generally were not individually associated with intraprostatic inflammation in controls. 6 Here, we investigated whether the previously studied variants in immune response genes are associated with prevalence and extent of intraprostatic inflammation among controls and with risk of lower-and highergrade prostate cancer in the finasteride arm of the PCPT.
Specifically, we evaluated 16 candidate SNPs in IL1β, IL2, IL4, IL6, IL8, IL10, IL12(p40), IFNG, MSR1, RNASEL, TLR4, and TNFA, and 7 tagSNPs in IL10 in 625 white prostate cancer cases and 532 white controls. As we did in the placebo arm, we also estimated serum PSA concentration by genotype and estimated the association between the SNPs and prostate cancer in men with low PSA levels to address concerns about PSA-associated detection bias.
| MATERIALS AND METHODS

| Study design and population
have prostate cancer detected. 7 All non-white controls were included, and remaining controls were frequency matched to cases on age, first-degree family history of prostate cancer, and treatment arm. Of the 1809 cases and 1809 controls, 765 cases and 765 controls were from the finasteride arm. 7 In this analysis, we included the 625 cases and 532 controls from the finasteride arm who were white and had adequate DNA and serum available for the larger set of research questions being investigated using this same nested case-control set. We did not include other racial/ethnic groups due to limited power to investigate SNP associations in such groups. Cases were categorized as lower grade (Gleason sum 2-6; N = 380) and higher grade (Gleason sum 7-10;
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| Genotyping
We previously published details on SNP selection and genotyping in the PCPT. 5 Table S1 . DNA was extracted from peripheral blood leukocytes using the Qiagen M48 robot and from serum using the AutoPure LS DNA Isolation Robot. SNPs were genotyped using the Illumina VeraCode GoldenGate 384-plex platform or Sequenom MassARRAY platform. SNPs that had >5.5% missing were excluded from the analysis. All SNPs were in Hardy-Weinberg equilibrium (HWE), except rs1143634 in IL1β (P = 0.03), rs3747531 in MSR1
(P = 0.01), and rs1554286 in IL10 (P = 0.03). Deviations from the expected genotype frequencies were minor for these SNPs, and thus, we included them in the analysis.
| Assessment of other study variables
Baseline demographics and lifestyle characteristics such as age, race/ethnicity, first-degree family history of prostate cancer, diabetes diagnosis, history of smoking and physical activity, and other medical factors for the cases and controls were ascertained from questionnaires completed at the start of the PCPT. Weight and height were measured at the start of the trial, from which body mass index (BMI; kg/m 2 ) was calculated.
In the present study we used inflammation data reported previously. 4 Briefly, inflammation was evaluated using Aperio ScanScope slide scanner (Aperio) to digitally assess the hematoxylin and eosin (H&E)-stained prostate tissue sections from the benign areas of the biopsy cores. A total of 6-10 cores were taken from each man, and an average of 3 cores were evaluated for the presence of any inflammatory cells (acute or chronic). This analysis included men with at least one biopsy core with inflammation or no cores with inflammation.
| Statistical analysis
We performed t-tests for continuous variables and chi-squared tests for categorical variables to determine case and control differences in baseline characteristics. We estimated odds ratios (ORs) and 95%
confidence intervals (CI) of total, lower-, and higher-grade prostate cancer using logistic regression adjusting for the matching factors age and family history. To address the possibility of detection bias resulting from associations between SNPs and serum PSA, we calculated mean serum PSA concentration by genotype in the controls and used linear regression to test for trend across genotype.
In a sub-analysis, we tested the association between SNPs and total, lower-, and higher-grade prostate cancer in men with a serum PSA concentration <2 ng/mL, to reduce the possibility of PSA-associated detection bias. In controls, we also determined whether the prevalence of carrying at least one minor allele differed between men with and without at least one biopsy core with inflammation using the chi-squared test.
Statistical analyses were conducted using the R packages SNPassoc 
| RESULTS
Characteristics of included prostate cancer cases and controls in the finasteride arm of the PCPT are shown in Table 1 . Cases and controls did not differ on age or family history, which were frequency-matching factors. Mean baseline serum PSA was higher among cases than controls (P < 0.0001). Cases and controls did not statistically significantly differ on history of diabetes, physical activity, BMI, or smoking status. Almost half of the cases were detected on for-cause biopsies and about a third were of higher Gleason sum.
| Candidate SNPs and prostate cancer risk
We examined the association between carrying one copy or two copies of the minor allele for the studied SNPs with total prostate cancer, and lower-or higher-grade disease (Supplement Tables S2 and   S3 ). Here we focus on the log-additive results (Table 2) . Some associations differed when restricting to men with low serum PSA (<2 ng/mL; Supplemental Table S4 ).
Several SNPs were associated with prostate cancer overall or by grade and associations persisted among men with low PSA. The minor allele (T) of rs1143634 in IL1β was possibly inversely associated with total prostate cancer (OR = 0.84, CI: 0.70-1.02, P-trend = 0.1) and lower-grade (OR = 0.82, CI: 0.66-1.02, P-trend = 0.07) ( Table 2 ), but not with higher-grade disease. In men with low PSA, the minor allele was statistically significantly inversely associated with total prostate cancer and lower-grade disease (Supplement Table S4 ). The minor allele (A) of rs4073 in IL8 was possibly inversely associated with total prostate cancer (OR = 0.89, CI: 0.75-1.04, P-trend = 0.1) and highergrade disease (OR = 0.81, CI: 0.64-1.01, P-trend = 0.06) ( Table 2) .
These associations were similar in men with low PSA, however, only the association with higher-grade disease was statistically significant (Supplement Table S4 ). The minor allele (T) of rs1800871 in IL10 was possibly positively associated with total prostate cancer (OR = 1.25, CI:
0.99-1.58, P-trend = 0.1) and lower-grade disease (OR = 1.26, CI:
0.96-1.64, P-trend = 0.09) ( Table 2) ; the association for total prostate cancer was statistically significant among men with low PSA (Supplement Table S4 ). Also, the minor allele (A) of rs1800872 in Table 2) ; these associations were the same in men with low PSA (Supplement Table S4 ). In all men, the minor 95% CI 0.32-0.95, P-trend = 0.03) ( Table 2) ; neither association was present in men with low PSA.
Other SNPs were not associated with prostate cancer or by grade, except among men with low PSA. SNPs in IL6 were not associated with prostate cancer overall or grade, except when restricting to men with low PSA, in whom the minor alleles of rs1800795 (C: OR = 0.70, 95%
CI 0.51-0.94; P-trend = 0.02; Supplement Table S4 ) and of rs1800797
(A: OR = 0.72, 95% CI 0.53-0.98, P-trend = 0.04; Supplement Table S4) were statistically significantly inversely associated with higher-grade disease. SNP rs321227 in IL12(p40) was not associated with total prostate cancer or disease grade, however, the minor allele (C) was possibly positively associated with higher-grade disease (OR = 1.31, 95% CI 0.94-1.82, P-trend = 0.1; Supplement Table S4 ) among men with low PSA.
None of the other SNPs (IL1β rs1143627; IL2 rs2069762; RNASEL rs486907; TLR4 rs4986790; TNFA rs1800629) was associated with prostate cancer overall or by grade, including in men with low PSA.
| IL10 tagSNPs and prostate cancer risk
Four of the seven IL10 tagSNPs that we selected appeared to be associated with prostate cancer risk. The minor alleles of rs3024496 (C) and rs1800890 (A) were inversely associated with risk of total and higher-grade disease (Table 2) ; the association in men with low PSA persisted only for total prostate cancer (Supplement Table S4 ). The minor allele (C) of rs3024509 was inversely associated with total (Table 2 ), but not higher-grade disease; no association was present in men with low PSA. The minor allele (T) of rs1554286 was possibly positively associated with total and higher-grade prostate cancer (Table 2) , including in men with low PSA (Supplement Table S4 ).
TagSNPs rs3024498, rs3021094, and rs1800894 were not associated with prostate cancer overall or grade of disease.
The haplotypes imputed from IL10 tag SNPs are shown in Table 3 .
The most common haplotypes were ATTCAGT (31% of controls), GCTCAGA (24% of controls), and ACTCAGA (17% of controls). Overall the distribution of haplotype frequencies did not differ (Table 3) between total cases and controls (score test P = 0. 
| Serum PSA concentration by genotype in controls
We calculated mean serum PSA concentration within a year prior to biopsy by genotype in controls (Table 4) to assess the likelihood of PSA-associated detection bias in the above reported associations. As expected for men taking finasteride, mean end-of-study serum PSA concentration was lower compared with baseline (Table 4) . PSA concentration increased with number of minor alleles in rs2069762 in IL2 (G; P-trend = 0.02), rs4073 in IL8 (A; P-trend = 0.03), and possibly in rs3212227 in IL12(p40) (C; P-trend = 0.1) and tagSNP rs3021094 in IL10 (C; P-trend = 0.1). PSA concentration possibly decreased with increasing number of minor alleles of rs1800629 in TNFA (A; P-trend = 0.08).
| SNPs and intraprostatic inflammation
We determined the prevalence of carrying at least one copy of the minor allele in men with and without at least one biopsy core with inflammation in the controls (Table 5 ). While none of the prevalences statistically significantly differed between men with and without inflammation, we did observe some possible differences in prevalence for candidate SNPs in IL6, IL10, and RNASEL, and tagSNPs in IL10.
| DISCUSSION
The purpose of this study was to examine whether SNPs in genes involved in the immune response are associated with risk of lower-and higher-grade prostate cancer, and with prevalence of intraprostatic inflammation among controls in the finasteride arm of the PCPT. We observed that select SNPs in IL4 (rs2243250) and MSR1 (rs3747531)
were associated with higher-grade disease; these associations were absent in men with low PSA. Also, SNPs in IL1β (rs1143634), IL10
(rs1800871, rs1800872, rs1800896), IFNG (rs2430561), and possibly IL8 (rs4073) were associated with risk and grade, including in men with low PSA. We also observed that SNPs in IL6 (rs1800795, rs1800797) and IL12(p40) (rs321227) were not associated with risk of total or higher-grade prostate cancer except in men with low PSA. Other SNPs were not associated with risk overall or in men with low PSA (IL1β rs1143627; IL2 rs2069762; RNASEL rs486907; TLR4 rs4986790; TNFA rs1800629). Four of the seven IL10 tagSNPs that we selected (rs3024496, rs1800890, rs3024509, rs1554286) appeared to be associated with prostate cancer risk in the finasteride arm; whether their associations persisted in men with low PSA varied. IL10
haplotypes were not associated with risk, except possibly with higher-grade disease among those with low PSA. We also noted associations between some SNP and PSA concentration in the controls, including for IL2 (rs2069762), IL8 (rs4073), and possibly IL12(p40) (rs3212227), IL10 (tagSNP rs3021094), and TNFA (rs1800629). We did not observe an association between the studied SNPs and intraprostatic inflammation in the controls in the finasteride arm. Given that we previously reported no association between the prevalence and the extent of intraprostatic inflammation and prostate cancer risk in the PCPT finasteride arm, 4 we had expected to find no association between SNPs involved in inflammation and prostate cancer risk. Our findings are not consistent with this expectation; we did observe some SNPs to be associated with risk. We also had expected to not find an association between these same SNPs and The associations between some of the selected SNPs and prostate cancer were consistent between the two arms of the trial (Supplement Table S6 ). In the finasteride and placebo arms, the minor allele (A) of rs4073 in IL8, which is associated with increased pro-inflammatory and pro-angiogenic IL-8 production, 8 was possibly inversely associated with higher-grade disease overall and among men with low PSA.
Given that IL-8 is proinflammatory, we might have hypothesized that a SNP producing higher circulating concentration would be associated with an increased, rather than decreased prostate cancer risk. In addition to observing an inverse association for this SNP in both of the trial, some 9, 10 but not all [11] [12] [13] [14] previous studies conducted among men presumably not enriched for finasteride use also reported inverse associations. In both arms of the trial, in men with low PSA, the minor alleles of rs1800871 (T) and rs180072 (A) in IL10, which are known to Also, the minor allele of rs3024496 was inversely associated with lower-grade disease in both arms. Consistent with the results in the placebo arm, SNPs rs1143627 in IL1β, rs2069762 in IL2, rs3024498
and rs1800894 in IL10, and rs1800894 in TNFA were not associated with total prostate cancer or grade of disease in all men and in men with low PSA in the finasteride arm.
With respect to differences in the association between these SNPs and intraprostatic inflammation in the controls by treatment arm, in the finasteride arm, we did not observe an association between the studied SNPs and intraprostatic inflammation, whereas in the placebo arm, we previously observed possible inverse associations of SNPs in IL2, IL10 (rs1800871), and RNASEL with inflammation. 6 While finasteride is known to stimulate an immune response 17, 18 and we previously observed a greater prevalence of inflammation in the finasteride rather than placebo arm of the PCPT, 4 how this drug might alter the link between variants in these immune response genes and intraprostatic inflammation is unclear.
With respect to differences in SNPs and serum PSA concentration in the controls by treatment arm, of the five SNPs associated with PSA concentration in the finasteride arm-rs2069762 in IL2, rs4073 in IL8, and possibly rs1800629 in TNFA, rs3212227 in IL12(p40), and tagSNP rs3021094 in IL10, 3-IL2, TNFA, and IL10 (rs3021094)-were also associated with PSA in the placebo arm. the associations between the SNPs and serum PSA in the controls, and differences in the associations of the SNPs with prostate cancer between the main analysis and the subanalysis in men with low PSA concentration. SNPs in IL1β, IL4, IL10 (rs1800871, rs1800872, rs1800896), IFNG, and MSR1 were associated or possibly were associated with risk of total or grade-specific disease in the main analysis in men with low PSA, and none of these SNPs was associated with PSA concentration, thus, it is unlikely that the associations for these SNPs are fully explained by PSA-associated detection bias. The positive association between the IL8 SNP and PSA concentration is unlikely to explain its possible inverse association with higher-grade prostate cancer. Further, when restricting to men with low PSA, the association for this IL8 SNP and higher-grade disease remained statistically significant, supporting that PSA-associated detection bias does not explain the association between this SNP and higher-grade disease. We also noted that SNPs in IL6 and IL12(p40) were or possibly were associated with risk of total and higher-grade disease only when restricting to men with low PSA. The IL12(p40) SNP was possibly associated with high PSA concentration, whereas, the minor alleles of SNPs in IL6 were not associated with PSA levels. Thus, the observed null association with higher-grade prostate cancer in the main analysis is unlikely to be due to the association with PSA. Thus, our data do not support a strong role for PSA-associated detection bias as an explanation for the associations between SNPs and prostate cancer in the finasteride arm.
| Strengths and limitations
To our knowledge, our study is the first to investigate the association between these SNPs and the risk of prostate cancer, and with intraprostatic inflammation among men taking finasteride.
We previously described the strengths of the PCPT for studies on genes involved in the immune response and prostate cancer 4,5 and With respect to the association between SNPs and intraprostatic inflammation, because prostate tissue was collected in the PCPT per the study protocol, including from men without clinical indication for prostate biopsy, we were uniquely able to examine this association among men taking finasteride. However, the sample size was small and the vast majority of the men treated with finasteride had inflammation present, and thus, chance could explain these null SNP-inflammation results. Furthermore, we investigated whether select SNPs were associated with only the presence of intraprostatic inflammation.
Future studies are needed to determine whether SNPs in genes involved with immune response are associated with specific immune cell types in finasteride users.
| CONCLUSION
In the PCPT finasteride arm, variation in genes involved in the immune response, including possibly IL8, IL10, and IL12(p40) as in the placebo arm, may be associated with prostate cancer, especially higher-grade disease. These SNPs were not however, associated with the presence of intraprostatic inflammation. We cannot fully rule out PSAassociated detection bias or chance due to multiple testing as explanations for our findings. 
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